NCT02042248View on ClinicalTrials.gov

A Phase I Study to Evaluate the Immunologic Response and Virologic Impact of AGS-004

PHASE1CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

March 31, 2014

Primary Completion Date

May 31, 2016

Study Completion Date

May 31, 2016

Conditions
HIV
Interventions
BIOLOGICAL

AGS-004

All participants in both arms will receive the same treatment and doses of AGS-004 in Step 2 at weeks 0, 4, 8, and 12.

Trial Locations (1)

27599

University of North Carolina, Chapel Hill

Sponsors

Collaborators (1)

Argos Therapeutics
All Listed Sponsors
collaborator

Argos Therapeutics

INDUSTRY

collaborator

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

lead

Cynthia L Gay, MD

OTHER

NCT02042248 - A Phase I Study to Evaluate the Immunologic Response and Virologic Impact of AGS-004 | Biotech Hunter | Biotech Hunter